Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Behring LLC

Division of CSL Ltd.
www.aventisbehring.com

Latest From Aventis Behring LLC

Unlocking Legalities: False-Claim Standards Continue To Evolve

The finer points of when exactly the US government can collect from a device company for selling it a bill of goods are under reconsideration, even as the fast pace of False Claims Act suits continues, attorneys with law firm Gibson Dunn concluded during a series of recent webinars.

Legal Issues Unlocking Legalities

CoGenesys Inc.

CoGenesys has licensed rights to albumin fusion proteins that improve the bioavailability of proteins better than other methods such as PEGylation, its founders believe. The start-up's pipeline presently contains a version of BNP for treating heart failure.
BioPharmaceutical

Aventis Antes Up in Antibodies

Aventis SA's oncology franchise is anchored by the blockbuster Taxotere. Sales of the drug comprise more than 8% of Aventis's core pharma business, and are currently growing more than 25% worldwide and in the US. Yet until recently, the firm had few other products with which to leverage its commercial infrastructure in oncology. It is therefore teaming up with ImmunoGen Inc. to create antibody-based oncology therapeutics using drug targets provided by both companies.
BioPharmaceutical

What Lies Behind the Curtain at HGS?

With Human Genome Sciences freed from obligations to share its genomics data exclusively with the 6-company human gene therapeutic consortium, HGS is set to look for its own new product-oriented alliances. But the 8-year-old company and its consortium have yielded only four compounds in clinical trials. HGS CEO William Haseltine says that the company can leverage its tremendous assets to strike potentially rich deals. The key question is how many human therapeutic proteins remain to be uncovered.
BioPharmaceutical Legal Issues
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Immune Disorders
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Centeon LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • CSL Ltd.
  • Senior Management
  • Ruedi E Waeger, PhD, CEO
    Henri F Mura, Chief Mktg. Officer
    James Fickenscher, Dir., Bus. Dev.
    Ulrich Delvos, MD, PhD, SVP, R&D & CSO
  • Contact Info
  • Aventis Behring LLC
    Phone: (610) 878-4000
    1020 First Ave.
    King of Prussia, PA 19406-1310
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register